Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
2025 · 2nd Quarter (Apr 1 - June 30)
BIOTECHNOLOGY INNOVATION ORGANIZATION
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Jun 18, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- bd5a248f-df63-47be-923d-fc88374378ed
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.